| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 895.3 | 851.6 |
| Profit before tax | 56.5 | 40.0 |
| Net income | 34.5 | 36.2 |
| EPS (diluted, $ a share) | $0.38 | $0.40 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -4.9% |
|---|---|
| Revenue, year on year | +5.1% |
10-Q filed with the SEC, NASDAQ: ACHC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Acadia Healthcare Company, Inc.: key numbers
- Share price
- $37.94Close, Nov 17
- Market cap
- $3.53B
- Shares outstanding
- 92.97MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Specialty Outpatient Facilities, NECSIC 8093
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Acadia Healthcare Company, Inc.
All →Acadia Healthcare Company Financial Results
Acadia Healthcare reported Q3 2026 revenue of $895.3 million, a 5.1% increase year-over-year, driven by strong performance in acute inpatient psychiatric facilities. While net income slightly decreased to $34.5 million, the company raised its full-year 2026 financial guidance based on positive operational momentum and facility expansions.
- Term
- Q3 2026
“Acadia delivered strong results in the third quarter, and our positive momentum is driving our increased full-year guidance. We remain focused on our key priorities, including expanding access to quality patient care and consistent operational execution with financial discipline.”
Debbie Osteen, Chief Executive Officer of Acadia
Acadia Healthcare Company Court & Legal Update
The U.S. District Court for the Middle District of Tennessee granted preliminary approval for a settlement of several consolidated stockholder derivative actions against Acadia Healthcare and certain individual defendants. The litigation, which includes cases in both Tennessee and Delaware, alleged breaches of fiduciary duty and securities law violations related to matters previously disclosed in 2025. The settlement aims to fully resolve and discharge all released claims nominally asserted on behalf of the company.
- Counterparty
- Robert Davydov, Margaret Pfenning, and John Solak